Vanda Pharmaceuticals Enters into an Exclusive Global License Agreement with AnaptysBio to Develop and Commercialize Imsidolimab

Shots:

• Vanda received exclusive rights to develop, manufacture & commercialize imsidolimab which has completed 2 P-III (GEMINI-1 & GEMINI-2) trials for generalized pustular psoriasis
• As per the terms, Anaptys will get $10M upfront, $5M for existing drug supply, & ~$35M in regulatory & sales milestones, plus 10% royalty on net sales, whereas Vanda will start technology transfer, manufacturing as well as BLA & MAA filings with the FDA & EMA in 2025
• In GEMINI-1, imsidolimab (750/300mg IV, single dose) vs PBO showed 53% vs 13% (750mg) & 53% (300mg) achieved GPPPGA (0/1; 1EP) at 4wks. GEMINI-2 followed 16 responders for 24 – 92wks.: 8 on imsidolimab (200mg, SC, Q1M) with sustained response & no flare; 8 on PBO with 25% sustained & 63% flared

Ref: PRNewswire | Image: AnaptysBio & Vanda Pharmaceuticals

Related News:- AnaptysBio and GSK Report P-III Trial Results of Jemperli (dostarlimab) for the Treatment of Primary Advanced or Recurrent Endometrial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com